Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

CDT Equity Inc.

NASDAQ: CDT · Life Sciences · 8 alerts · CIK 1896212

Share price
$0.3770Close, Nov 16
Market cap
$2.38M
Shares outstanding
6.31MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CDT Equity Inc. filings on SEC EDGAR ↗

6:32 PM ET 10-Q
Financial Results

CDT Equity Q3 2026 Results: Net Loss of $4.58M, Loss Narrows

CDT Equity Inc. reported a net loss of $13.3 million for the nine months ended September 30, 2026, compared to $17.9 million in the prior year. The company significantly expanded its balance sheet through a $153.5 million equity method investment, resulting in total assets increasing from $5.7 million to $158.7 million.

Key figure
Net loss $4.58M
4:30 PM ET 8-K
Reverse Stock Split

CDT Equity Reverse Stock Split

CDT Equity Inc. stockholders approved a proposal to authorize the board of directors to effect a reverse stock split at a ratio ranging from 1-for-2 to 1-for-100. Stockholders also approved the issuance of common stock under Nasdaq Listing Rule 5635 related to convertible notes and warrants issued to J.J. Astor & Co.

8:00 AM ET 8-K
M&A Deal

CDT Equity M&A Deal with Corvus Capital Limited

CDT Equity Inc. received a letter from former CEO Dr. Andrew Regan and Corvus Capital Limited indicating an intent to propose a non-binding acquisition of all outstanding common stock at $2.00 per share. The Board of Directors plans to form a Special Committee of independent directors to evaluate the potential proposal and other strategic alternatives.

Counterparty
Corvus Capital Limited
9:02 AM ET 8-K
Reverse Stock Split

CDT Equity Reverse Stock Split

CDT Equity Inc. has filed a certificate of amendment to effectuate a 1-for-20 reverse stock split of its common stock, effective November 5, 2026. The split is intended to maintain compliance with Nasdaq Listing Rules, reducing the outstanding share count from approximately 20.4 million to 1.0 million shares. Trading on a split-adjusted basis is expected to begin on November 6, 2026, under the existing ticker symbol 'CDT'.

8:16 AM ET 8-K
Business Update

CDT Equity Business Update

CDT Equity entered into an evaluation agreement with Manoira Corporation to analyze clinical-stage compounds AZD1656 and AZD5904 for potential use in animal health products. As part of the arrangement and other corporate obligations, the company issued shares to Manoira to settle a $195,000 payment, as well as shares to a service provider and former CEO Dr. Andrew Regan for severance.

Counterparty
Manoira Corporation
8:00 AM ET 8-K
Loan & Debt

CDT Equity $6.75M Debt Financing with J.J. Astor & Co.

CDT Equity Inc. issued a $6.75 million senior secured convertible promissory note to J.J. Astor & Co., to be funded in two tranches. The note is secured by a first priority lien on company assets and includes weekly installment payments starting October 14, 2026. The lender has the right to convert the debt into common stock at a discount to the market price, subject to a floor price of $0.18354.

Value
$6.75M
Counterparty
J.J. Astor & Co.
Term
through March 24, 2027
8:15 AM ET 8-K
Reverse Stock Split

CDT Equity Reverse Stock Split

CDT Equity Inc. has announced a 1-for-25 reverse stock split of its common stock, effective September 28, 2026. The split is intended to increase the per-share price to ensure continued compliance with the Nasdaq minimum bid-price requirement. Trading on a split-adjusted basis is expected to begin on September 29, 2026, reducing the outstanding share count to approximately 1.12 million shares.

5:16 PM ET 8-K
Loan & Debt

CDT Equity $2.13M Debt Financing with J.J. Astor & Co.

CDT Equity Inc. issued a $2.13 million senior secured convertible promissory note to J.J. Astor & Co., receiving net proceeds of approximately $1.5 million. The note matures in March 2027 and is secured by a first priority lien on company assets, with repayment supported by proceeds from the company's existing at-the-market offering program. In connection with the debt, the company also issued warrants to purchase approximately 3.47 million shares of common stock at $0.25 per share.

Value
$2.13M
Counterparty
J.J. Astor & Co.
Term
through March 1, 2027

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.